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Abstract
Vitamin D deficiency has been linked to an increased risk of a wide range of adverse health outcomes.
The active form of vitamin D has an important role in calcium metabolism and in bone mineralisation,
but the evidence for other health outcomes is mixed, with the strongest effects seen in the weakest
epidemiological study designs. There are plausible pathways whereby vitamin D deficiency can impair
immune function, resulting in both overactivity and increased risk of autoimmune disease, as well as
immune suppression with poorer resistance to infection. Vitamin D status may influence the bacterial
flora that constitute the microbiome and affect immune function through this route. Exposure of the
skin to ultraviolet radiation causes the production of a range of chemicals, including vitamin D, and new
research is exploring possible vitamin D-independent immunomodulatory pathways.
Introduction
Vitamin D deficiency is reportedly widespread across the
world, a consequence of urbanisation and indoor life-
styles, migration of dark-skinned populations to low sun
environments when their skin type has evolved to be
optimal for high sun environments, and possibly sun
protection strategies to curb rising skin cancer incidence
rates. Over the last 10-15 years, increased risk of a wide
range of health outcomes has been linked to vitamin D
deficiency, although in many cases the links remain rather
weak. After the undisputed importance of vitamin D for
bone health, the strongest evidence is probably for an
increased risk of immune disorders in association with
vitamin D deficiency. Here we briefly review some of that
evidence, examine recent literature on possible mechan-
istic pathways and propose potential explanations for
some of the conflicting results in this area.
Clues from epidemiology
Indications that vitamin D may be associated with
disorders of human immune function often originate
from observations of geographic variation in disease
occurrence. In many regions of the world, vitamin D is
primarily synthesised in the skin following sun exposure
(specifically UV-B irradiation). Levels of UV-B radiation
vary strongly according to distance from the equator
(latitude) and time of year, with higher levels as the sun
is closer to being directly overhead, that is, nearer the
equator, in summer, and during the middle of the day.
Thus, higher latitude is often taken as a proxy for both
lower levels of ultraviolet radiation (UVR) and lower
vitamin D status. Latitudinal gradients, where the
incidence or prevalence of a disease increases with
increasing distance from the equator (lower UV-B
radiation), are described for multiple sclerosis [1], type
1 diabetes [2], the autoimmune vasculitides [3], the
inflammatory bowel diseases [4], and asthma [5]. Null
or inverse associations are also described for other
autoimmune disorders [6,7]. Both UVR and vitamin D
(in its active form 1,25(OH)2D, see Figure 1) have
immunomodulatory effects [8] that provide a plausible
mechanism whereby higher levels could decrease the risk
of autoimmune diseases (see section on mechanisms,
below) and, through the same pathways, could impair
the immune response to vaccination or infection [9,10].
Accordingly, the effectiveness of BCG vaccination for
tuberculosis is reported to increase with increasing
latitude (lower UVR) [11].
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Observational studies have, in general, supported these
ecological patterns. In case-control studies, participants
with one of these autoimmune diseases tend to report
lower past sun exposure, and/or have lower vitamin D
status (measured as the blood concentration of the inter-
mediarymetabolite, 25(OH)D, see Figure 1), than healthy
controls (see for example recent reviews [12,13]). How-
ever, for at least some of the immune-related diseases, it
is difficult to determine whether low sun exposure or
vitamin D cause, or are caused by, the disease. There is
a smaller body of evidence from prospective cohort
studies, in particular, because these diseases caused by
immune dysfunction are uncommon and require large
numbers of participants to be under observation for a
sufficient time to achieve required sample sizes. This is a
stronger study design because the direction of causality is
established, that is, the low vitamin D status precedes the
onset of the health outcome. Lower vitamin D status has
been linked to increased risk of multiple sclerosis (see case
study [14]) and to type 1 diabetes [15], although not all
studies show a protective association [16].
Despite these relatively coherent findings from ecologic
and observational studies, and plausible biological
Figure 1. The synthesis of vitamin D following UVB irradiation of the skin
UVB photons are absorbed by 7-dehydrocholestrol in the epidermis and are converted into pre-vitamin D which undergoes a thermal isomerisation to
formvitamin D. This then undergoes two hydroxylation reactions, first in the liver to form 25-hydroxyvitamin D (25(OH)D) and then in the kidney to form
the active metabolite, 1,25-dihydroxyvitamin D (1,25(OH)2D). Serum 25(OH)D levels are used to determine vitamin D status. VDR, vitamin D receptor.
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mechanisms, trials of vitamin D supplementation for
the prevention of immune-related diseases have largely
returned null results [17]. It is worth considering the
challenges of a true prevention trial for these diseases,
they are uncommon, possibly with long subclinical
phases, with the optimum time for intervention unknown,
amongst other difficulties. Prevention trials to date have
focused on high-risk populations where the disease
process may already be underway, or on preventing
progression in those who have already developed the
disease, where different pathological processes may be
operating (see comment in [18]). Nevertheless, there is not
yet compelling evidence from these studies that vitamin D
supplementation ameliorates any immune-related
disease.
Mechanisms by which 1,25(OH)2D may
regulate immune cell function
It is generally believed that all immune cell types can
respond to 1,25(OH)2D. This belief is driven by recogni-
tion of cellular expression of the vitaminD receptor (VDR),
the finding of multiple primary 1,25(OH)2D target genes
in immune cells and the discovery thatmany immune cells
(macrophages, dendritic cells, T and B lymphocytes) can
convert 25(OH)D to 1,25(OH)2D through CYP27B1
activity and therefore provide significant local levels of
1,25(OH)2D for functional outcomes (for review [8,19]).
The amount of 1,25(OH)2D producedmay depend on the
ability of immune cells to express CYP27B1 and other
enzymatic machinery of the vitamin D pathway, including
the CYP24A1 deactivation enzyme. As an example, in vitro
stimulated macrophages produced more 1,25(OH)2D
than dendritic cells, which expressed truncated CYP27B1
transcripts resulting in lower CYP27B1 protein levels, and
also expressed increased levels of CYP24A1 mRNA [20].
Despite in vitro studies reporting significant biological
effects of 1,25(OH)2D on immune cells (frequently under
ideal conditions using potentially supra-physiological
concentrations of 1,25(OH)2D), the question remains as
to the real biological effects of 1,25(OH)2D in vivo. The
issue is further complicated by the finding that human
cells are frequently used for in vitro investigations, but
the majority of studies reporting the biological effects of
1,25(OH)2D in vivo have been performed in the experi-
mental mouse. There are also differences between the
regulatory potential of supplemented levels versus homeo-
static concentrations of 1,25(OH)2D. An extreme is seen in
micenot expressing theVDR; theyhave increased sensitivity
to autoimmune diseases [21] but this finding contributes
little information to the extent by which 1,25(OH)2D
may dose-dependently regulate VDR-expressing cells.
Furtherwork is required tobetter understand the regulatory
properties of 1,25(OH)2D because, as summarised below,
many of the findings in vitro have not been replicated
in vivo. A central concept is that 1,25(OH)2D stimulates
innate immunity and suppresses adaptive immunity, but
the mechanisms by which these outcomes are achieved
vary with different experimental models.
Exposure of differentiating dendritic cells to 1,25(OH)2D
prevents their full maturation [22]. However, debate
remains surrounding the properties of these “tolero-
genic” dendritic cells and their ability to interfere with
T cell division and promotion of T regulatory cell (TReg)
production and expansion [23]. Some studies suggest
that existing CD25+Foxp3+TReg cells proliferate rather
than TReg cell development occurring de novo [24]. Other
investigators report that, whilst high non-physiological
concentrations of 1,25(OH)2D (10
-6M) and long culture
periods (2 weeks) are required for induction of Foxp3+
TReg populations, the frequency in vitro of Foxp3+ TRegs
can be increased by supplementation of cells with TGFb
(2 ng/ml) and lower concentrations of 1,25(OH)2D
(10-7M) [25]. Upon 1,25(OH)2D administration in vivo,
the properties of the exposed dendritic cells are varied.
In one model, 1,25(OH)2D was applied topically to the
skin of mice [26]. After 18 hours, when the dendritic cells
would havemigrated to the draining nodes, the capacity of
these dendritic cells to take up, process and present antigen
to co-cultured T cells was not modified. However, upon
transfer to new naïve mice, these dendritic cells induced
significantly smaller ear-swelling responses, as a measure
of contact hypersensitivity. The dendritic cells from the
mice treated with topical 1,25(OH)2D expressed increased
levels of indoleamine 2,3-dioxygenase which may explain
this altered dendritic cell property in vivo [26].
T cells may also directly respond to 1,25(OH)2D. Naïve
T cells express low levels of the VDR that is up-regulated
by antigen-specific triggering of T cell receptors and
contributes to priming of naïve cells (for review [27]). As
VDR expression can also inhibit the transcription of the
interleukin (IL)-2 gene, this may represent another point
of immune regulation by 1,25(OH)2D. Homing recep-
tors on T cells may be altered by 1,25(OH)2D [28] and a
recent analysis of the impact of 1,25(OH)2D, given by
oral gavage to mice immunised with myelin oligoden-
drocyte glycoprotein to induce experimental autoim-
mune encephalomyelitis, suggests that this may be one
of the most important immunoregulatory roles of 1,25
(OH)2D [29]. These authors found that 1,25(OH)2D
prevented accumulation of inflammatory cells into the
central nervous system, although 1,25(OH)2D did not
affect the activation of the pathogenic interferon-g and
IL-17-producing T cells in lymph nodes, spleen or the
immunisation site, that is, the dramatic systemic immune
reaction to myelin oligodendrocyte glycoprotein was
not altered. There was no induction of Foxp3+ TReg by
Page 3 of 11
(page number not for citation purposes)
F1000Prime Reports 2014, 6:118 http://f1000.com/prime/reports/b/6/118
1,25(OH)2D. More specifically, 1,25(OH)2D seemed to
maintain the activated Th1/Th17 cells in the circulation
and prevented them from crossing the blood brain
barrier. The mechanism proposed was a significant and
reversible reduction in expression of the chemokine
receptor, CXCR3 [29]. Modulation of other chemokine
receptors on T cells by 1,25(OH)2D has also been reported
[30]. Further, 1,25(OH)2D can reduce the migration of
macrophages by suppressing the expression of CCR2, the
receptor for monocyte chemotactic protein-1, principally
by reducing endoplasmic reticulum stress [31].
TRegs may also be direct targets of 1,25(OH)2D. Using
topical delivery to shaved skin, 1,25(OH)2D enhanced the
ability of CD4+CD25+ cells in the skin draining lymph
nodes to down-regulate T helper type 2-driven asthmatic
responses, upon transfer to allergen-sensitised mice [32].
Further investigations found that 1,25(OH)2D, in the
presence of IL-2, directly enhanced the regulatory potential
of CD4+CD25+ T cells to control immune responses [33].
Circulating levels of 1,25(OH)2D are a log fold lower than
those of 25(OH)D and are not sufficient for immunor-
egulation; it is generally proposed that 25(OH)D is
converted locally to sufficient levels of 1,25(OH)2D to
achieve biological activity. Mast cells have recently been
identified, with macrophages, dendritic cells and T and B
lymphocytes, to express CYP27B1 for local 1,25(OH)2D
production [34]. However, the level of vitamin D binding
protein, and its affinity to 25(OH)D, can also restrict
the availability of 25(OH)D to dendritic cells and possibly
other cells [35]. Cells from individuals with various
vitamin D-binding protein (VDBP) variants were studied
and for individuals with the strong 25(OH)D binding
variant, the availability of 25(OH)D to dendritic cells was
restricted, resulting in less dendritic cell-T cell interaction.
In summary, we still have much to learn about the
mechanisms bywhich 1,25(OH)2Dmay regulate immune
cell activity in vivo.
Multiple sclerosis: a case study
One of the earliest indications of an association between
vitamin D and disorders of human immune function
was the geographical variation in prevalence of multiple
sclerosis, as first described in 1922 [36]. Additional
studies since then have confirmed a latitudinal gradient,
with higher incidence or prevalence at locations further
from the equator in both the northern and southern
hemispheres [1,37,38]. Building on these ecological
studies, observational studies confirmed increased risk of
multiple sclerosis in association with lower sun exposure
[39,40] and with lower 25(OH)D levels [14,41]. Yet,
despite plausible immunological pathways whereby
vitamin D (through stimulation of TRegs and dampening
of T helper type 1 over-reactivity) could diminish the risk
of multiple sclerosis or disease activity, vitamin D sup-
plementation trials have shown immunological [42] and
radiological [43], but not clinical, benefit for people with
multiple sclerosis.
It is challenging to differentiate between vitamin
D-dependent and -independent pathways in the effect of
sun exposure on disease risk. Limited success in vita-
min D supplementation trials suggests that vitamin D-
independent effectsmay contributemore strongly to disease
risk. In the mouse, the onset of experimental autoimmune
encephalomyelitis, amodel formultiple sclerosis, was signi-
ficantly delayed following chronic irradiation with sub-
erythemal doses of UV-B radiation [44]. Serum 25(OH)D
levels were only slightly elevated and suppression of disease
did not occur following oral administration of 25(OH)D
[44]. However, when 1,25(OH)2D was administered (in
food), it suppressed the development of experimental
autoimmune encephalomyelitis, but only when given at
levels that caused hypercalcaemia; one hypothesis was
that it was hypercalcaemia per se that was important to
disease suppression. TReg-inducing tolerogenic dendritic
cells, induced by UV-B irradiation of the skin, were required
for amelioration of experimental autoimmune encephalo-
myelitis [45]. Serum 25(OH)D levels and sun exposure
have been shown to be independently associated with the
onset of central nervous system demyelination in humans
[41] and brain and spinal cord lesions detected bymagnetic
resonance imaging in people with multiple sclerosis [46].
Additionally, while increased sun exposure during child-
hood was inversely associated with risk of multiple
sclerosis, there was no decreased risk associated with
intake of vitamin D supplements during childhood [40].
Sun exposure during childhood may be a more significant
factor for disease risk than sun exposure in adulthood.
On the basis of migration studies, the risk of developing
multiple sclerosismayalreadyhavebeendeterminedbefore
the age of 15 years [47]. Migrants moving from a country
with high prevalence of multiple sclerosis to a country with
a lower prevalence retain the high risk of their country of
origin if migration occurs after the age of 15, but have
the lower risk of their new country if they migrate before
15 years of age [47,48]. However, sun exposure even earlier
than childhood may be an important factor in risk of
multiple sclerosis. An association between month of birth
and risk of multiple sclerosis has been observed in both the
northern [49,50] and southern [51] hemispheres, suggest-
ing an important role for sun exposure in utero for the risk
of developing the disease in later life. In the experimental
autoimmune encephalomyelitis animal model, vitamin D
supplementation in the postnatal period delays the onset
of the disease [52] but there is no evidence that antenatal
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vitamin D supplementation has any effect. Although child-
hood vitamin D levels and sun exposure appear to be
important determinants of the risk of disease onset, higher
25(OH)D levels early in the disease course may predict the
rate of disease progression in multiple sclerosis [53].
An indirect pathway: vitamin D, immunity and
the microbiome
Following interactions with pathogens, immune cells
like monocytes can synthesise 1,25(OH)2D, possibly
through activation of specialised immune receptors like
the toll-like receptors [54], or following stimulation with
other immune-modulators like TGFb or interferon-g [55].
This stimulates autophagy (the degradation of internal
cell structures) and the synthesis of antimicrobials, such
as cathelicidin, for bacterial killing [54]. Antimicrobial
proteins are expressed at common epithelial surfaces,
including the gut, skin, urinary tract and lung [55].
Cathelicidins target gram-positive and -negative bacteria,
viruses and fungi bymembranedisruption, and are expres-
sed by neutrophils, macrophages, natural killer cells, mast
cells and epithelial cells [56,57]. They arewidely conserved
in mammals - the LL-37 peptide in humans and cathelin-
related antimicrobial protein in mice. Transcription of
the CAMP, the gene encoding cathelicidin, is regulated by
the vitamin D receptor through 1,25(OH)2D in humans,
but not rodents [58]. Induced antimicrobials such as
cathelicidin and ß-defensin-4 [54], can also act as
immune-modulators [57]. This pathway (Figure 2) may
be dependent upon levels of circulating 25(OH)D, the
substrate for 1,25(OH)2D, or of CYP27B1, the enzyme
controlling this reaction; however, in vivo evidence for this
is lacking. Vitamin D supplementation increases serum
levels of 25(OH)D and cathelicidin [58–60], suggesting
that systemic elimination of pathogenic microbes is
possible; but, supplementation trials aiming to control
infections with Mycobacterium tuberculosis have not been
successful [61]. In vitro bacterial targets of vitamin D
include M. tuberculosis, Pseudomonas aeruginosa and other
species [54], and there are reported benefits of vitamin D
for the control of viral or fungal infections, especially those
of the lower respiratory tract like influenza A [8].
The microbiome constitutes the commensal bacteria that
colonise various parts of the body like the gastrointestinal
[62] and respiratory [63] tracts and skin [64]. In murine
models, 1,25(OH)2D may be able to suppress tissue infla-
mmation by altering the microbiome [65, 66]. Vitamin D
deficiency increased the severity of colitis and bacterial
numbers in the colons of mice [66] and, in male mice with
allergic airway disease (modelling allergic asthma),
vitamin D deficiency increased lung inflammation and
bacterial numbers [65]; these effects were reversed by
vitamin D supplementation [65]. Other studies have
linked vitaminDwith specific changes to the composition
of the bacterial flora in the gut microbiome. The absence
of the 1a-hydroxylase enzyme in CYP27B1-/- mice with
colitis increased the burden of the Proteobacterium phylum
(including Helicobaceteraceae species) in faeces [67]. These
observations were linked with diminished numbers of
tolerogenic CD103+ dendritic cells in the lamina propria,
cells that shape the TReg cell repertoire of the gut [68].
Treatment of these mice with 1,25(OH)2D (1.25 mg/100 g
diet) suppressed colitis severity and Helicobaceteraceae
numbers. Similar observations have been made in
humans, whereby increased dietary vitamin D changed
the composition of faecal microbiota [69]. Collectively,
these studies suggest that vitamin D is instrumental in
regulating the microbiome of the lungs and gut, and is
entwined with the maintenance of immune tolerance.
As murine studies are starting to illustrate in the gut and
lungs, the interplay between vitamin D, the microbiome
and immune tolerance may also curb skin inflammation.
Abnormal microbiomes have been detected in diseased
skin, including psoriatic plaques and atopic dermatitis
[70]. Topical 1,25(OH)2D or related analogues are used
to treat psoriasis and may be useful for treating atopic
dermatitis and other inflammatory skin diseases [71].
The mechanisms by which 1,25(OH)2D suppresses skin
inflammation associated with these diseases may at least
partially involve promotion of immune tolerance with
the activation of TRegs [72]. An added complexity in
psoriasis is the levels of cathelicidins that accumulate in
the dermis, which can have pro-inflammatory effects at
high concentrations [73]. We anticipate that a deeper
understanding of how vitamin D modulates the micro-
biomes of the skin and other tissues will come through
ongoing vitamin D supplementation trials [74].
Other studies suggest that the microbiome may modify
the capacity of tissue regulation by vitamin D. In rodent
models, probiotics can upregulate expression of the VDR
in the colon, reducing inflammation and delaying the
transition to dysplasia and cancer [75]. Furthermore,
vitamin D supplementation may suppress the develop-
ment of intestinal tumours in susceptible mice [76]. In a
clinical setting, expression of the VDR was decreased in
patients with dysplasia and colitis-associated colorectal
cancer [77], suggesting that inflammation may also
downregulate the VDR. These data suggest that not only
can vitamin D modulate tissue inflammation through
modifications to the microbiome, but the reverse is also
possible—the microbiome and inflammation can change
the responsiveness of tissues to vitamin D through regu-
lation of the VDR. 1,25(OH)2D also upregulates the VDR
[78], suggesting that this reduced responsiveness may be
reversed by supplementation.
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Why doesn’t vitamin D supplementation
decrease disease risks?
In the face of supportive observational and mechanistic
evidence, why doesn’t vitamin D supplementation
decrease disease risks? A broad range of responses have
been proposed to answer this question with a particular
focus on reverse causality or confounding. For the
former, it has been proposed that inflammation causes
depression of 25(OH)D levels [17] and this accounts
for the association between low 25(OH)D levels and
Figure 2. A proposed network of interactions between vitamin D and the microbiome that may sway the development of immune
tolerance or tissue inflammation
Activation of immune cells like monocytes and epithelial cells by bacterial-derived products (e.g. lipopolysaccharide [LPS], derived from the outer membrane
of gram-negative bacteria) and cytokines (such as transforming growth factor-ß [TGFß] and interferon-g [IFNg], results in local synthesis of 1,25(OH)2D, and
immune tolerance through effects on TReg cells. 1,25(OH)2D may also have effects on innate pathways including synthesis of antimicrobials and activation of
autophagy, which together may modulate the local microbiome. Alternatively, microbiome changes, like those induced following the use of probiotics, may regulate
the responsiveness of immune cells to vitamin D by enhancing the expression of the vitamin D receptor (VDR) thus reducing tissue inflammation.
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increased disease risk. For evidence arising from case-
control studies, where disease has already occurred in
the cases, this is certainly plausible; however, in the
published cohort studies that show a link between low
25(OH)D and development of disease, the latter often
occurs many years after the blood sample was taken (e.g.
[14]). That asymptomatic disease of sufficient severity
to lower 25(OH)D levels was present at this much earlier
time seems unlikely. Residual confounding from physical
activity or a generally healthier lifestyle may provide an
explanation for the significant associations seen in observa-
tional studies for some disease outcomes, but neither of
these is a known risk factor for autoimmune diseases (and
thus could not be a confounder). In addition, with respect
to an ability of supplemental vitamin D to alter the course
of autoimmune diseases, there is debate about the validity
of biochemical or cellular markers from blood as truly
representative of disease status.
There are several potential other explanations that need
to be considered and each has important implications
for research and clinical practice.
Independent beneficial effects of sun exposure
Exposure to UVR and to 1,25(OH)2D both cause immune
suppression that is relevant to some (Th-1) autoimmune
diseases [8]. Low levels of 25(OH)D seen in observational
studies may be a marker for low levels of sun exposure,
with the latter also important for disease risk. Vitamin D
supplementation studies take account only of vitamin D,
without the possibly necessary additional benefits of sun
exposure.
Importance of the life stage
There is some evidence to support the importance of
early life exposures in the risk of autoimmune diseases. It
is challenging to adequately study these exposures.
However, several studies suggest that low vitamin D
status or low levels of ambient UVR during the in utero
period [49], or during childhood [40], are associated
with increased risk of immune-related disorders. The lack
of any protective effect of vitamin D supplementation
in adulthood may be because the processes necessary
for disease have already been put in place much earlier
in life.
Genetic variation in the physiological response to
vitamin D supplementation
A high degree of individual variability in the 25(OH)D
response to vitamin D supplementation has been
described that is the result of demographic, environmental
and genetic factors [79]. The effect of these factors on the
physiological, or disease-relevant, response to vitamin D
supplementation has not been explored.
Corruption of the vitamin D system by the disease
Mismanagement of the vitaminD systemmay arise during
some pathological processes. For example, in leprosy, the
Mycobacterium leprae may hijack the use of cellular
microRNAs to block vitamin D-induced antimicrobial
production [80]. In addition, in some granulomatous
diseases, such as sarcoidosis,CYP27B1 is over-expressed in
disease-activated macrophages [81] causing high levels of
1,25(OH)2D and increased risk of hypercalcemia.
Free versus total serum 25(OH)D
Vitamin D metabolites in blood are largely tightly bound
to VDBP, with a small proportion of the total concentra-
tion loosely bound to albumin or unbound (free) [82].
Traditionally the level of total 25(OH)D has been
considered the best estimate of vitamin D status, but
recent studies have suggested that the “bioavailable”
(albumin-bound and free) 25(OH)D concentration may
be more relevant to health and disease [83]. The ratio of
total to bioavailable 25(OH)D depends on several VDBP-
related genes and health states, such as liver disease [84],
type 1 diabetes [85], and pregnancy [86].
Vitamin D2 versus vitamin D3 versus active 1,25(OH)2D
There is mixed evidence on the different physiological
potency of vitamin D3 compared to D2 (for example,
[87,88]). Inmost observational studies that have separately
quantified 25(OH)D2 and 25(OH)D3, levels of the former
are generally low or undetectable [89]. Most recent vitamin
D supplementation trials use vitamin D3, suggesting that
any differences between D2 and D3 do not account for
the different findings from observational and vitamin D
supplementation trials. The active form, 1,25(OH)2D, is
seldom used in supplementation trials. It has a short
half-life in blood, can cause hypercalcaemia and raising
1,25(OH)2D levels in blood initiates its deactivation by
the 24-hydroxlyase enzyme [90,91].
The study participants were not vitamin D deficient
at baseline
If there is a causal association between vitamin D and
disease risks, increased risk occurs in association with
vitamin D deficiency [92]. Vitamin D supplementation
trials commonly include participants who do not have
low baseline 25(OH)D levels and whose disease risk
would thus be unlikely to change much [91]. Future
work could focus on supplementation trials including
only people with low baseline levels of 25(OH)D.
Risks to supplementing people who are already
vitamin D sufficient
Several studies have now reported U-shaped or reverse
J-shaped curves for a range of disease outcomes; for exam-
ple, for all-cause mortality, both high and low 25(OH)D
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levels are associated with increased risk [92]. Similarly, in
one RCT of high-dose vitamin D supplementation there
was an increased risk of falls and fractures [93]. It is likely
that there is a loss of study power and a risk of harm if
participants in vitamin D supplementation trials already
have adequate 25(OH)D levels at baseline [91].
Higher 25(OH)D levels are not maintained over a
disease-relevant time period
Many of the diseases for which increased risk has been
linked to vitamin D deficiency develop over a long
period of time, for example, cancers, and cardiovascular
disease. Yet vitamin D supplementation trials are generally
relatively short-term, with supplementation for only 1-2
years. This discrepancy in timing may contribute to the
failure of vitamin D supplementation trials to decrease the
risk of disease onset.
Conclusion
The jury is still out on the importance of vitamin D for
immune function: both for vitaminDdeficiency increasing
the risk of autoimmune diseases and viral infections
through loss of regulatory adaptive immune functions, as
well as for high vitamin D levels decreasing the risks of
tuberculosis and infections with other intracellular patho-
gens through upregulation of innate immunity. Effects
may not be direct, but could work through alterations in
the microbiome, or be only partly vitamin D-mediated,
with exposure to UVR itself also important. Many of the
outstanding questions will be difficult or impossible to
resolve in human studies, such as the importance of the
timing of any intervention. Pragmatic solutions such as
movingwhole populationdistributions of 25(OH)D levels
to above a minimum of 40-50 nmol/L may be required,
with any beneficial effects only apparent retrospectively.
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